Search Results
Results found for "Brian Kobilka"
- G-protein-coupled receptors as therapeutic targets for glioblastoma
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumour in adults. Despite this, the prognosis remains poor, with an impacted quality of life during treatment coupled with brain
- Odorant G protein-coupled receptors as potential therapeutic targets for adult diffuse gliomas ...
functions distinct from odor perception, and may contribute to the pathogenesis of disorders including brain Glioma is the most common adult malignant brain tumor and requires novel therapeutic strategies to improve Here, we outlined the expression of brain ORs and investigated OR expression levels in glioma.
- Diversity and specificity in location-based signaling outputs of neuronal GPCRs
by which members of the G protein-coupled receptor (GPCR) family respond to neurotransmitters in the brain
- Exciting GPCR Events for Next Year! + GPCR Weekly Rocket Launch ⦿ Oct 28 - Nov 3, 2024
Exclusive access to private groups Over 30 recorded talks from Symposia - that's a lot of brain food To Design Novel GPCR- Targeted Antibody Therapeutics Using Generative AI Zombie Fungi Hijack Hosts’ Brains punctata GPCRs in Neuroscience Neuron specific quantitation of Gαolf expression and signaling in murine brain
- Illuminating the draggable GPCR-ome
Bryan Roth There are 10 open tickets available. Get yours now!
- In Vitro and In Silico Characterization of Kurarinone as a Dopamine D 1A Receptor Antagonist and ...
Alterations in the expression and/or activity of brain G-protein-coupled receptors (GPCRs) such as dopamine Since studies have indicated that flavonoids can target brain GPCRs and provide neuroprotection via inhibition
- Chemogenetic stimulation of the G i pathway in astrocytes suppresses neuroinflammation
functional role of the astrocytic Gi pathway is not clear, as the literature is conflicting depending on the brain between enhanced calcium transients and the inflammatory phenotype of astrocytes observed in the inflamed brain
- Neurotransmitters: Potential Targets in Glioblastoma
September 2022 "For decades, glioblastoma multiforme (GBM), a type of the most lethal brain tumor, has
- AELIS PHARMA launches their IPO for €25 million
fundraising gives us the means to achieve our ambitions: to become a leading player in the field of brain
- Emerging approaches for decoding neuropeptide transmission
in high-resolution techniques to investigate peptidergic transmission and expression throughout the brain
- Synthesis and characterization of an orally bioavailable small molecule agonist of the apelin recept
This compound has vastly reduced brain penetration and is devoid of significant off-target liability.
- Adenosine receptor signalling in Alzheimer's disease
The adenosine A1 and A2A receptors are expressed in the human brain and have a proposed involvement in
- Job Opportunity Spotlight #1: Principal Scientist, In Vitro Pharmacology
Crinetics hires people with big brains and small egos.”
- Adenosine receptor signalling in Alzheimer's disease
The adenosine A1 and A2A receptors are expressed in the human brain and have a proposed involvement in
- Dopamine activates astrocytes in prefrontal cortex via α1-adrenergic receptors
In other brain regions, astrocytes sense diverse neurotransmitters and neuromodulators and, in turn,
- The regulation of PKA signaling in obesity and in the maintenance of metabolic health
Mouse models have provided invaluable information on the roles for PKA subunits in brain and key metabolic
- N-Acyl Amides from Neisseria meningitidis and Their Role in Sphingosine Receptor Signaling
mechanisms N. meningitidis employ to manipulate the immune system, translocate the mucosal and blood-brain
- The Bile Acid Membrane Receptor TGR5 in Cancer: Friend or Foe?
TGR5 is widely distributed in the brain, lung, heart, liver, spleen, pancreas, kidney, stomach, jejunum
- Neuropeptide S Encodes Stimulus Salience in the Paraventricular Thalamus
accumbens shell and structures in the prefrontal cortex and amygdala, which were previously linked to the brain
- GPR84 signaling promotes intestinal mucosal inflammation via enhancing NLRP3 inflammasome activation
immune system, including neutrophils, monocytes, and macrophages in the periphery and microglia in the brain
- Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment ...
treatment of neuropathic pain, a debilitating condition caused by damage to the nerves outside of the brain
- A2B Adenosine Receptor Enhances Chemoresistance of Glioblastoma Stem-Like Cells under Hypoxia: New..
New Insights into MRP3 Transporter Function "Glioblastoma is the most common and aggressive primary brain
- Design and validation of recombinant protein standards for quantitative Western blot analysis of...
quantitative Western blot analysis of CB1 receptor expression on crude synaptosomes of the adult rat brain
- GPCR voltage dependence controls neuronal plasticity and behavior
G-protein coupled receptors (GPCRs) play a paramount role in diverse brain functions.
- Signaling pathways activated by sea bass gonadotropin-inhibitory hormone peptides in COS-7 cells...
GnIH) system in the European sea bass, Dicentrarchus labrax, which exerted an inhibitory action on the brain-pituitary-gonadal
- Increased Anxiety-like Behaviors in Adgra1-/- Male But Not Female Mice are Attributable to...
We found that Adgra1 is highly and exclusively expressed in the brain, suggesting that Adgra1 may be
- Differences across sexes on head-twitch behavior and 5-HT2A receptor signaling in C57BL/6J mice
However, the pharmacokinetic properties of DOI differed among sexes - brain and plasma concentrations
- Co-activation of GPCRs facilitate GIRK-dependent current
Recordings in brain slices have shown that co-activation using saturating concentrations of agonists
- β-arrestin1 promotes tauopathy by transducing GPCR signaling, disrupting microtubules and autophagy
and mGluR2-mediated increase in pathogenic tau but also show that β-arrestin1 levels are increased in brains
- Target Residence Time: The Hidden Driver of In Vivo Efficacy
In structured, diffusion-restricted environments (e.g. brain, tumors), drugs don't just leave slowly;



